Navigation Links
Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions
Date:3/5/2009

SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- On the surface, the thick, red, scaly, itchy plaques of psoriasis -- which have been shown to have a significant negative impact on a person's overall quality of life -- may not appear to pose a serious health risk for patients. However, a growing body of research suggests that psoriasis patients are at an increased risk of developing serious medical conditions, including cardiovascular disease and diabetes, particularly when their psoriasis is severe.

Speaking today at the 67th Annual Meeting of the American Academy of Dermatology (Academy), dermatologist Joel M. Gelfand, MD, MSCE, FAAD, assistant professor of dermatology at the University of Pennsylvania School of Medicine in Philadelphia, spoke about this complex skin condition and its relationship to other serious medical conditions.

Dr. Gelfand explained that for the last two decades, research has shown that excessive inflammation is a critical feature of psoriasis. This discovery has led to innovative approaches to treating psoriasis, with therapies targeting selected areas of the immune system that are over-active in psoriasis patients. Excess inflammation also is present in other common conditions, such as hardening of the arteries, heart attacks, stroke, obesity and diabetes -- which may explain why some psoriasis patients may be at an increased risk for developing these other serious conditions.

Studies show the link between patients with severe psoriasis and diabetes, heart attack and coronary artery disease occurs independent of traditional risk factors for these other conditions -- such as obesity, smoking or high blood pressure.

Furthermore, Dr. Gelfand's recent research suggests that patients with severe psoriasis may have shorter life expectancies than non-psoriasis patients. Specifically, he found that those with severe psoriasis may die three to five years earlier than patients who do not have the disease.

"Patient education is critical in the early detection and management of these related conditions, many of which can be controlled with proper medical care," said Dr. Gelfand. To minimize the risk of developing associated medical conditions, Dr. Gelfand recommended that psoriasis patients lead a healthy lifestyle, avoid smoking, maintain an ideal body weight and get routine screenings for cardiovascular risk factors -- such as blood pressure and cholesterol checks.

"We need to educate psoriasis patients about the increased risk of cardiovascular disease so the prevention efforts can be instituted," explained Dr. Gelfand.

Experts in the dermatology and cardiology communities have issued consensus statements advocating that physicians educate patients with psoriasis -- particularly if the disease is severe -- about the potential association of psoriasis with other serious diseases, such as diabetes and cardiovascular disease.

Dr. Gelfand added that further research is needed to better determine how skin disease severity and activity affect the risk of developing these associated conditions and whether successful treatment of psoriasis alters the risks.

About Psoriasis

Psoriasis affects nearly 7 million Americans and can start at any age, although it most commonly starts in early adulthood (20s and 30s). Psoriasis has a genetic component, as approximately 40 percent of patients with psoriasis have a family history of the disease. While the exact cause of psoriasis is unknown, it is believed to occur due to an interaction of multiple genes, the immune system and the environment, according to Dr. Gelfand. The disease can be localized, affecting only the elbows or scalp, or can involve skin on the entire body.

To learn more about psoriasis, visit the PsoriasisNet section of www.skincarephysicians.com, a Web site developed by dermatologists that provides patients with up-to-date information on the treatment and management of disorders of the skin, hair and nails.

Headquartered in Schaumburg, Ill., the American Academy of Dermatology (Academy), founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 15,000 physicians worldwide, the Academy is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. For more information, contact the Academy at 1-888-462-DERM (3376) or www.aad.org.


'/>"/>
SOURCE American Academy of Dermatology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties
2. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
3. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
4. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
5. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
6. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
7. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
8. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
11. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Calif. , Jan. 19, 2017 Accuray ... its CyberKnife® and TomoTherapy® Systems continue to set the ... received the highest composite overall user satisfaction rating among ... the Q4 2016 MD Buyline Market Intelligence Briefing™. The ... the highest composite ratings among industry peers for 11 ...
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
Breaking Medicine Technology:
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming ... friends, and community. “Coming Home 2017” will be held on Friday January ...
(Date:1/21/2017)... Austin, Texas (PRWEB) , ... January 21, 2017 ... ... surgeries performed by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its ... features two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... to enhance people’s everyday lives, recently attended the January ECRM Trade Show in ... Science is known for its large range of supplements that keep the body ...
Breaking Medicine News(10 mins):